{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:57:01Z","timestamp":1759334221045,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Department of Respiratory Medicine"},{"name":"Juntendo University Graduate School of Medicine"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.lungcan.2020.08.014","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T11:32:27Z","timestamp":1597923147000},"page":"122-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-0149","authenticated-orcid":false,"given":"Yusuke","family":"Okuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehito","family":"Shukuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichiro","family":"Iwasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisaku","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Hino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Yamanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Fukuizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0825-5166","authenticated-orcid":false,"given":"Toshiyuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Nukiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2020","series-title":"RARE CANCERS EUROPE","key":"10.1016\/j.lungcan.2020.08.014_bib0005"},{"first-page":"65","year":"2018","series-title":"Center for Cancer Control and Information Services, National Cancer Center. CANCER STATISTICS IN JAPAN 2017","key":"10.1016\/j.lungcan.2020.08.014_bib0010"},{"issue":"3","key":"10.1016\/j.lungcan.2020.08.014_bib0015","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jtho.2019.11.013","article-title":"The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors","volume":"15","author":"Ruffini","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2020.08.014_bib0020","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ejcts\/ezv239","article-title":"Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study","volume":"49","author":"Hishida","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"issue":"10","key":"10.1016\/j.lungcan.2020.08.014_bib0025","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1634\/theoncologist.2017-0586","article-title":"G. North East Japan Study, Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study","volume":"23","author":"Ko","year":"2018","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.lungcan.2020.08.014_bib0030","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1634\/theoncologist.2019-0593","article-title":"Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study","volume":"25","author":"Tateishi","year":"2020","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.lungcan.2020.08.014_bib0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.lungcan.2020.08.014_bib0040","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2020.08.014_bib0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.lungcan.2020.08.014_bib0050","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.lungcan.2020.08.014_bib0055","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2020.08.014_bib0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2020.08.014_bib0065","doi-asserted-by":"crossref","first-page":"546","DOI":"10.21037\/tcr.2016.09.35","article-title":"Impact of metastasis site for survival of patients with advanced thymic epithelial tumors","volume":"5","author":"Cheng","year":"2016","journal-title":"Translational Cancer Research"},{"issue":"4","key":"10.1016\/j.lungcan.2020.08.014_bib0070","first-page":"737","article-title":"Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience","volume":"15","author":"Yamamoto","year":"1999","journal-title":"Int J Oncol"},{"key":"10.1016\/j.lungcan.2020.08.014_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer","volume":"106","author":"Bagley","year":"2017","journal-title":"Lung Cancer"},{"issue":"47","key":"10.1016\/j.lungcan.2020.08.014_bib0080","doi-asserted-by":"crossref","first-page":"77404","DOI":"10.18632\/oncotarget.12677","article-title":"Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy","volume":"7","author":"Nakamura","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.lungcan.2020.08.014_bib0085","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.lungcan.2020.08.014_bib0090","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.lungcan.2020.08.014_bib0095","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"10183","key":"10.1016\/j.lungcan.2020.08.014_bib0100","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.lungcan.2020.08.014_bib0105","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.lungcan.2020.08.014_bib0110","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.21873\/anticanres.12779","article-title":"Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer","volume":"38","author":"Shiroyama","year":"2018","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.lungcan.2020.08.014_bib0115","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00432-019-03104-w","article-title":"The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases","volume":"146","author":"Kitadai","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.lungcan.2020.08.014_bib0120","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.lungcan.2020.08.014_bib0125","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2020.08.014_bib0130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.lungcan.2020.08.014_bib0135","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2020.08.014_bib0140","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.cllc.2014.10.006","article-title":"Response to cytotoxic chemotherapy in patients previously treated with palliative-intent chemotherapy for advanced thymic carcinoma","volume":"16","author":"Okuma","year":"2015","journal-title":"Clin Lung Cancer"},{"issue":"suppl_5","key":"10.1016\/j.lungcan.2020.08.014_bib0145","first-page":"v747","article-title":"Durable Anti-Tumor Activity of the Multi-Targeted Inhibitor Lenvatinib in Patients with Advanced or Metastatic Thymic Carcinoma; Preliminary Results from a Multicenter phase II (REMORA) Trial","volume":"30","author":"Itoh","year":"2019","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1016\/j.lungcan.2020.08.014_bib0150","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1016\/j.jtho.2016.07.011","article-title":"Response of Malignant Thymoma to Sorafenib","volume":"11","author":"Bolzacchini","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2020.08.014_bib0155","first-page":"129","article-title":"Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib","volume":"8","author":"Stjepanovic","year":"2014","journal-title":"Biologics"},{"issue":"35","key":"10.1016\/j.lungcan.2020.08.014_bib0160","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1200\/JCO.2015.60.7481","article-title":"Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg\u2019s Discovery","volume":"33","author":"Muggia","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2020.08.014_bib0165","doi-asserted-by":"crossref","first-page":"18581","DOI":"10.1038\/s41598-019-54906-4","article-title":"Clinical prognostic scores for patients with thymic epithelial tumors","volume":"9","author":"Veraar","year":"2019","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.lungcan.2020.08.014_bib0170","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00776-010-1506-9","article-title":"Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma","volume":"15","author":"Sugiura","year":"2010","journal-title":"J Orthop Sci"},{"issue":"12","key":"10.1016\/j.lungcan.2020.08.014_bib0175","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report","volume":"14","author":"Dingemans","year":"2019","journal-title":"J Thorac Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220305870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220305870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:46:00Z","timestamp":1759236360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220305870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":35,"alternative-id":["S0169500220305870"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.08.014","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}